Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA showcases a promising outlook due to its innovative pipeline focused on neurodegenerative diseases, particularly with the upcoming EVOKE trial for the NLRP3 program, which could significantly increase interest if outcomes are favorable for Alzheimer's disease patients. Additionally, the company's PD active immunotherapy ACI-7104.056 has demonstrated a remarkable 20-fold increase in antibodies against pathogenic variants of aSyn, indicating strong potential for effective treatment options. Furthermore, the focus on safer delivery methods for monoclonal antibodies through titration dosing enhances the viability of their products, positioning AC Immune favorably in a rapidly evolving treatment landscape for Alzheimer's disease.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, suggesting significant ongoing financial challenges. The company is exposed to inherent risks typical of the biopharmaceutical industry, such as potential adverse clinical results and regulatory hurdles, which could adversely impact its development pipeline. Furthermore, the evolving landscape of commercial markets, characterized by increased price sensitivity, may complicate the successful commercialization of its product candidates.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.